IP Library Granted Patent US 8,912,150
Granted Patent B2
US 8,912,150 · App. 13/924,155 · Granted Dec 16, 2014

Ribosome structure and protein synthesis inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,912,150
App. No.
13/924,155
Granted
Dec 16, 2014
Kind
B2
Abstract

The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. Thus, the methods and compositions of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism.

Claims (7)

1. A protein synthesis inhibitor comprising:

a first binding domain having a surface that mimics or duplicates a surface of linezolid that binds with a first contact site in a large ribosomal subunit; and

a second binding domain having a surface that mimics or duplicates a surface of a macrolide that binds with a second contact site in the ribosomal subunit,

wherein the first domain is attached to the second domain so as to permit both the first domain and the second domain to bind with its respective contact site thereby to disrupt protein synthesis in a ribosomal subunit, and wherein the protein synthesis inhibitor has a molecular weight of less than about 1,500 and an IC 50 lower than about 50 μM.

2. The inhibitor of claim 1 , wherein the inhibitor has a molecular weight in the range from about 250 to about 1500.

3. The inhibitor of claim 1 , wherein the inhibitor has an IC 50 in the range from about 0.001 μM to about 50 μM.

4. The inhibitor of claim 1 , wherein the macrolide is selected from the group consisting of azithromycin, tylosin, spiramycin, erythromycin, and carbomycin.

Assignments (10)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (PATENTS) AT REEL 054836 AND FRAME 0765 AND REEL 061314 AND 0459 Recorded Aug 29, 2025
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: MELINTA THERAPEUTICS, LLC
Reel/Frame 072772/0097 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2022
From: MELINTA THERAPEUTICS, LLC
To: SILICON VALLEY BANK
Reel/Frame 061314/0459 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 22, 2020
From: MELINTA THERAPEUTICS, LLC
To: SILICON VALLEY BANK
Reel/Frame 054836/0765 →
SECURITY INTEREST Recorded Mar 19, 2019
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; MELINTA SUBSIDIARY CORP.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 048637/0784 →
MERGER AND CHANGE OF NAME Recorded Aug 30, 2018
From: MELINTA THERAPEUTICS, INC.; MELINTA SUBSIDIARY CORP.
To: MELINTA SUBSIDIARY CORP.
Reel/Frame 046752/0975 →
RELEASE OF SECURITY INTEREST Recorded Jan 5, 2018
From: SUCHARD SA LLC
To: MELINTA SUBSIDIARY CORP. (F/K/A MELINTA THERAPEUTICS, INC.)
Reel/Frame 044547/0939 →
SECURITY INTEREST Recorded Jun 28, 2017
From: MELINTA THERAPEUTICS, INC.
To: SUCHARD SA LLC
Reel/Frame 042854/0753 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2013
From: SUTCLIFFE, JOYCE A; OYELERE, ADEGBOYEGA K; IPPOLITO, JOSEPH A
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 031780/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2013
From: STEITZ, THOMAS A; MOORE, PETER B
To: YALE UNIVERSITY
Reel/Frame 031780/0339 →
CHANGE OF NAME Recorded Oct 17, 2013
From: RIB-X PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 031432/0123 →